Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM)

Today's Latest Price: $11.94 USD

0.21 (1.79%)

Updated Sep 25 4:00pm

Add EPZM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

EPZM Stock Summary

  • With a price/sales ratio of 87.61, Epizyme Inc has a higher such ratio than 97.03% of stocks in our set.
  • With a year-over-year growth in debt of 731.59%, Epizyme Inc's debt growth rate surpasses 97.34% of about US stocks.
  • Revenue growth over the past 12 months for Epizyme Inc comes in at -41.13%, a number that bests only 5.46% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Epizyme Inc, a group of peers worth examining would be CTIC, HTBX, BCYC, DSPG, and QUIK.
  • Visit EPZM's SEC page to see the company's official filings. To visit the company's web site, go to www.epizyme.com.
EPZM Daily Price Range
EPZM 52-Week Price Range

EPZM Stock Price Chart Technical Analysis Charts


EPZM Price/Volume Stats

Current price $11.94 52-week high $27.82
Prev. close $11.73 52-week low $9.73
Day low $11.61 Volume 737,006
Day high $12.10 Avg. volume 1,069,074
50-day MA $13.03 Dividend yield N/A
200-day MA $17.68 Market Cap 1.21B

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/Time News Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about Epizyme Inc that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, Sept. 14, 2020 at 3:45 p.m. ET. A live webcast will be available in the investor section of the company's website at www.epizy

Business Wire | September 8, 2020

Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

Yahoo | August 5, 2020

Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call Transcript

Epizyme, Inc. (EPZM) Q2 2020 Earnings Conference Call August 4, 2020, 8:30 am ET Company Participants Alicia Davis - IR, THRUST Strategic Communications Rob Bazemore - President & CEO Matt Ros - Chief Strategy & Business Officer Paolo Tombesi - CFO Shefali Agarwal - CMO Conference Call Participants Peter Lawson...

SA Transcripts on Seeking Alpha | August 4, 2020

Recap: Epizyme Q2 Earnings

Shares of Epizyme (NASDAQ:EPZM) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share decreased 9.43% over the past …

Benzinga | August 4, 2020

Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights and will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details of both events are as follows: Second Quarter 2020 Financial Results: Manageme

Business Wire | July 28, 2020

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo -5.01%
3-mo -26.52%
6-mo -23.02%
1-year 17.40%
3-year -34.40%
5-year -3.16%
YTD -51.46%
2019 299.35%
2018 -50.92%
2017 3.72%
2016 -24.47%
2015 -15.10%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6532 seconds.